SCHEMBL6340449

SCHEMBL6340449

CSc1cc(C(C)(C)C)nn1C(=O)c1ccc(Cl)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ENPP3 O14638 4/20 0.49
ALPL P05186 4/20 0.49
XIAP P98170 4/20 0.49
F2 P00734 3/20 0.47
ALDH1A1 P00352 2/20 0.47
HPGD P15428 2/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
ENPP1 P22413 2/20 0.46
ELANE P08246 2/20 0.46
KMT2A Q03164 3/20 0.44
GAA P10253 1/20 0.44
KLK7 P49862 1/20 0.44
RAB9A P51151 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
KLK14 Q9P0G3 1/20 0.44
KLK5 Q9Y337 1/20 0.44
ST14 Q9Y5Y6 1/20 0.44
MAPT P10636 4/20 0.44
TP53 P04637 2/20 0.43
MAPK13 O15264 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6350971 0.82 ENPP3 (0.52) ENPP3ALPLXIAPF2ALDH1A1
SCHEMBL11257725 0.78 GRN (0.40) ALDH1A1GAAMAPTMAPK13MAPK12
SCHEMBL11254406 0.73 ACHE (0.42) ALDH1A1MAPT
SCHEMBL1225270 0.70 KMT2A (0.50) ENPP3ALPLXIAPF2ALDH1A1
SCHEMBL11257275 0.69 GRN (0.36) SMN1; SMN2NPSR1MAPTCNR2L3MBTL1
SCHEMBL10973639 0.67 F2 (0.60) ENPP3ALPLXIAPF2ALDH1A1
SCHEMBL9479546 0.64 ENPP3 (0.45) ENPP3ALPLXIAPF2ALDH1A1
SCHEMBL6054028 0.64 ENPP3 (0.43) ENPP3ALPLXIAPALDH1A1SMN1; SMN2
SCHEMBL12359808 0.64 KDM4E (0.47) MAPTMAPK13MAPK12MAPK11MAPK14
SCHEMBL7744788 0.63 GRN (0.67) MAPTMAPK13MAPK12MAPK11MAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050096372-A1 Small-molecule modulators of hepatocyte growth factor/scatter factor activities PILLARISETTI SIVARAM (US) 2005-05-05 US disclosed
US-6855728-B2 Small-molecule modulators of hepatocyte growth factor / scatter factor activities NORTH SHORE-LONG ISLAND JEWISH HEALTH SYSTEM (US) 2005-02-15 US disclosed
US-20030216459-A1 Small-molecule modulators of hepatocyte growth factor / scatter factor activities THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH 2003-11-20 US disclosed
EP-1355921-A2 MODULATORS OF CELLULAR PROLIFERATION AND ANGIOGENESIS, METHODS FOR USE AND IDENTIFICATION THEREOF North Shore-Long Island Jewish Health System (US) 2003-10-29 EP disclosed
WO-2002002593-A2 MODULATORS OF CELLULAR PROLIFERATION AND ANGIOGENESIS, METHODS FOR USE AND IDENTIFICATION THEREOF NORTH SHORE-LONG ISLAND JEWISH HEALTH SYSTEM (US) 2002-01-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030216459-A1 Small-molecule modulators of hepatocyte growth factor / scatter factor activities HGF, HDGF, MET ENPP3 4055/4885ALPL 997/4885XIAP 1625/4885
US-20050096372-A1 Small-molecule modulators of hepatocyte growth factor/scatter factor activities HGF, HDGF, MET ENPP3 4055/4885ALPL 997/4885XIAP 1625/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.